HTG Molecular Diagnostics (OTCPK:HTGM.Q) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

HTGM.Q Panoramica delle azioni

HTG Molecular Diagnostics, Inc. è una società di scienze biologiche che si concentra sulla medicina di precisione.

HTGM.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $3K )

I ricavi sono diminuiti del 28.2% nell'ultimo anno

Le azioni sono altamente illiquide

Gli ultimi report finanziari risalgono a più di un anno fa

HTG Molecular Diagnostics, Inc. Concorrenti

Pear Therapeutics

OTCPK:PEAR.Q

US$142.0

SOAFEE

OTCPK:SOFE

US$33.8k

MediXall Group

OTCPK:MDXL

US$101.9k

ETAO International

OTCPK:ETAO.F

US$1.5k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per HTG Molecular Diagnostics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.0002
Massimo di 52 settimane	US$0.36
Minimo di 52 settimane	US$0.0001
Beta	2.67
1Variazione di 1 mese	0%
Variazione a 3 mesi	-86.67%
Variazione di 1 anno	-99.89%
3Variazione a 3 anni	-100.00%
Variazione a 5 anni	-100.00%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

Rendimenti per gli azionisti

	HTGM.Q	US Healthcare Services	US Mercato
7D	0%	-2.0%	0.6%
1Y	-99.9%	0.3%	32.1%

Ritorno vs Industria: HTGM.Q ha avuto una performance inferiore rispetto al US Healthcare Services che ha registrato un rendimento -5.8 % nell'ultimo anno.

Rendimento vs Mercato: HTGM.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 25.4 % nell'ultimo anno.

Volatilità dei prezzi

Is HTGM.Q's price volatile compared to industry and market?
HTGM.Q volatility
HTGM.Q Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	9.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di HTGM.Q è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di HTGM.Q nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	54	John Lubniewski	www.htgmolecular.com

HTG Molecular Diagnostics, Inc. è una società di scienze biologiche che si concentra sulla medicina di precisione. L'azienda offre strumenti, materiali di consumo e software che automatizzano l'elaborazione dei campioni e la profilazione di vari target molecolari. I suoi pannelli di profilazione molecolare commercializzati includono il pannello HTG Transcriptome Panel; il pannello HTG EdgeSeq precision immuno-oncology panel; il saggio HTG EdgeSeq miRNA whole-transcriptome assay; il saggio HTG EdgeSeq DLBCL cell of origin assay EU; il pannello HTG EdgeSeq Oncology Biomarker Panel; il pannello HTG immune response e il pannello HTG mouse mRNA tumor response.

HTG Molecular Diagnostics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di HTG Molecular Diagnostics con la sua capitalizzazione di mercato?
HTGM.Q statistiche fondamentali
Capitalizzazione di mercato	US$442.00
Guadagni(TTM)	-US$20.15m
Ricavi(TTM)	US$6.21m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

HTGM.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HTGM.Q Conto economico (TTM)
Ricavi	US$6.21m
Costo del fatturato	US$11.13m
Profitto lordo	-US$4.92m
Altre spese	US$15.23m
Guadagni	-US$20.15m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-9.10
Margine lordo	-79.14%
Margine di profitto netto	-324.28%
Rapporto debito/patrimonio netto	1,452.4%

Come si è comportato HTGM.Q nel lungo periodo?

Vedi performance storica e confronto

HTGM.Q Panoramica delle azioni

Premi

Analisi del rischio

HTG Molecular Diagnostics, Inc. Concorrenti

OTCPK:PEAR.Q

US$142.0

OTCPK:SOFE

US$33.8k

OTCPK:MDXL

US$101.9k

OTCPK:ETAO.F

US$1.5k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83